The IMMUNE Commune Survey

Thank you for taking this survey about your experience with immunotherapy for yourself or a loved one. When questions include "you," it means the patient's experience. Your answers help us understand how to improve studies and care. We are especially interested in any side effects, which are also called "adverse events". The Immune Commune survey will take about 5 minutes to complete.

Here are immunotherapy drugs we are most interested in:
- “Pembro”, also called Keytruda (pembrolizumab)
- "Nivo", also called Opdivo (nivolumab) - Libtayo (cemiplimab)
- "Ipi", also called Yervoy (ipilimumab) - Loqtorzi (toripalimab)
- Bavencio (avelumab) - Opdualag (relatlimab)
- Imfinzi (durvalumab) - Tencentriq (atezolizumab)
- Imjudo (tremelimumab) - Tevimbra (tislelizumab)
- Jemperli (dostarlimab) - Zynyz (retifanlimab)

Your participation is completely voluntary. There are no foreseeable risks with this project. If you feel uncomfortable answering a question, you can skip it or withdraw from the survey at any point.

It is very important for us to hear your opinions! Your responses will be coded and confidential. Results will be reported only for the whole group. If you have questions at any time, please contact us at INSTITUTE@OneCancerPlace.org.

Thank you very much for your time. Please click on the Continue button below.

Custom Title